Daniel Von-Hoff

Summary

Affiliation: Translational Genomics Research Institute
Country: USA

Publications

  1. pmc Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
    Daniel D Von Hoff
    TGen Virginia G Piper Cancer Ctr, 445 N Fifth St, Suite 600, Phoenix, AZ 85004, USA
    J Clin Oncol 29:4548-54. 2011
  2. pmc Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling
    Matthew S Creamer
    Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    BMC Syst Biol 6:107. 2012
  3. pmc Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs
    Alexis Christoforides
    Translational Genomics Research Institute, Neurogenomics Division, Phoenix, AZ 85004, USA
    BMC Genomics 14:302. 2013
  4. pmc Learning contextual gene set interaction networks of cancer with condition specificity
    Sungwon Jung
    Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA
    BMC Genomics 14:110. 2013
  5. pmc Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
    David O Azorsa
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona 85259, USA
    J Transl Med 7:43. 2009
  6. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
  7. pmc RuleMonkey: software for stochastic simulation of rule-based models
    Joshua Colvin
    Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    BMC Bioinformatics 11:404. 2010
  8. ncbi request reprint What's new in pancreatic cancer treatment pipeline?
    Daniel D Von Hoff
    Translational Genomics Research Institute TGen, 45 North 5th Street, Suite 600, Phoenix, AZ 85004, USA
    Best Pract Res Clin Gastroenterol 20:315-26. 2006
  9. ncbi request reprint Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    David W Nyman
    Department of Pharmacology Toxicology, Division of Hematology Oncology, Arizona Cancer Center University of Arizona Health Sciences Center, Tucson, USA
    J Clin Oncol 23:7785-93. 2005
  10. doi request reprint Pancreatic cancer--could it be that simple? A different context of vulnerability
    Daniel D Von Hoff
    Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Cancer Cell 16:7-8. 2009

Research Grants

  1. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2009
  2. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
  3. Targets to Therapeutics in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
  4. Workshop on Methods in Clinical Cancer Research
    Daniel Von Hoff; Fiscal Year: 2007
  5. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2007
  6. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2006
  7. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
  8. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel D Von Hoff; Fiscal Year: 2010

Detail Information

Publications56

  1. pmc Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
    Daniel D Von Hoff
    TGen Virginia G Piper Cancer Ctr, 445 N Fifth St, Suite 600, Phoenix, AZ 85004, USA
    J Clin Oncol 29:4548-54. 2011
    ..Subsequent preclinical studies investigated the changes involving the pancreatic stroma and drug uptake...
  2. pmc Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling
    Matthew S Creamer
    Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    BMC Syst Biol 6:107. 2012
    ..To overcome this problem, the rule-based modeling approach has been developed for representing interactions within signaling networks efficiently and compactly through coarse-graining of the chemical kinetics of molecular interactions...
  3. pmc Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs
    Alexis Christoforides
    Translational Genomics Research Institute, Neurogenomics Division, Phoenix, AZ 85004, USA
    BMC Genomics 14:302. 2013
    ....
  4. pmc Learning contextual gene set interaction networks of cancer with condition specificity
    Sungwon Jung
    Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA
    BMC Genomics 14:110. 2013
    ....
  5. pmc Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
    David O Azorsa
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona 85259, USA
    J Transl Med 7:43. 2009
    ..Combinations of gemcitabine with other chemotherapeutic drugs or biological agents have resulted in limited improvement...
  6. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
    ....
  7. pmc RuleMonkey: software for stochastic simulation of rule-based models
    Joshua Colvin
    Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    BMC Bioinformatics 11:404. 2010
    ..Software implementing such methods is now needed for the simulation and analysis of rule-based models of biochemical systems...
  8. ncbi request reprint What's new in pancreatic cancer treatment pipeline?
    Daniel D Von Hoff
    Translational Genomics Research Institute TGen, 45 North 5th Street, Suite 600, Phoenix, AZ 85004, USA
    Best Pract Res Clin Gastroenterol 20:315-26. 2006
    ..With the level of investigational activity in pancreatic cancer it is very likely that several new therapeutic approaches to the disease will be forthcoming...
  9. ncbi request reprint Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    David W Nyman
    Department of Pharmacology Toxicology, Division of Hematology Oncology, Arizona Cancer Center University of Arizona Health Sciences Center, Tucson, USA
    J Clin Oncol 23:7785-93. 2005
    ..This study determined the maximum-tolerated dose (MTD) of ABI-007 monotherapy administered weekly (three weekly doses, repeated every 4 weeks) and assessed the pharmacokinetics of paclitaxel administered as ABI-007...
  10. doi request reprint Pancreatic cancer--could it be that simple? A different context of vulnerability
    Daniel D Von Hoff
    Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Cancer Cell 16:7-8. 2009
    ..Could this finding provide us with a new method to attack pancreatic cancer?..
  11. doi request reprint Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers
    Daniel D Von Hoff
    Translational Genomics Research Institute TGen, Scottsdale, AZ 85259, USA
    J Clin Oncol 28:4877-83. 2010
    ....
  12. ncbi request reprint A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
    Tomislav Dragovich
    Section of Hematology Oncology, University Medical Center and Arizona Cancer Center, 1515 N Campbell Ave, PO Box 245024, Tucson, AZ 85724, USA
    Cancer Chemother Pharmacol 58:759-64. 2006
    ....
  13. doi request reprint Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimen repository
    Michael J Demeure
    Scottsdale Healthcare Cancer Surgery, Scottsdale, AZ, USA
    Pancreas 39:949-54. 2010
    ..This article summarizes the key hurdles encountered and solutions we found in the process of developing a successful multi-institution biospecimen repository...
  14. pmc Advancing a clinically relevant perspective of the clonal nature of cancer
    Christian Ruiz
    Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Proc Natl Acad Sci U S A 108:12054-9. 2011
    ..We propose that our high-definition analyses of the genomes of distinct clonal populations of cancer cells in patients in vivo can help guide diagnoses and tailor approaches to personalized treatment...
  15. ncbi request reprint Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor
    Linda Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    J Immunother 28:376-81. 2005
    ..027 mg/m2. NBI-3001 at 0.016 mg/m2 was well tolerated. Low circulating levels of NBI-3001, coupled with rising NAB titers, may have contributed to the lack of response in tumors that express IL-4R...
  16. ncbi request reprint Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells
    Steven L Warner
    College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    Mol Cancer Ther 5:2450-8. 2006
    ....
  17. ncbi request reprint Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells
    Hong Wang
    Pancreatic Cancer Research Laboratory, Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Cancer Res 66:9722-30. 2006
    ..The results of microarray gene expression profiling and quantitative real-time reverse transcription-PCR suggest that cyclin B/CDC2 and minichromosome maintenance complexes might be the downstream cellular targets of UA62001...
  18. doi request reprint Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer
    Amanda F Baker
    College of Medicine, Hematology Oncology, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Pancreas 36:178-86. 2008
    ..To investigate the expression of thioredoxin-interacting protein (TXNIP) during hypoxia and its dependency on hypoxia-inducible factor 1alpha (HIF-1alpha) in pancreatic cancer cell lines...
  19. ncbi request reprint A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:5182-9. 2006
    ..We conducted a dose escalation study of HMN-214 in patients with advanced cancer to assess the safety profile and pharmacokinetics of HMN-214 and to establish the maximum tolerated dose...
  20. ncbi request reprint Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells
    Philip L Lorenzi
    Genomics and Bioinformatics Group, Room 5056B, 37 Convent Drive, Bethesda, MD 20892, USA
    Mol Cancer Ther 5:2613-23. 2006
    ..Overall, this pharmacogenomic/pharmacoproteomic study suggests the use of l-ASP for treatment of a subset of ovarian cancers (and perhaps other tumor types), with ASNS as a biomarker for patient selection...
  21. ncbi request reprint Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Tomislav Dragovich
    Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Cancer Chemother Pharmacol 60:295-303. 2007
    ..The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with pancreatic cancer and other solid tumors...
  22. ncbi request reprint Identification of a novel inhibitor of urokinase-type plasminogen activator
    Ming Zhu
    Division of Clinical Translational Research, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Mol Cancer Ther 6:1348-56. 2007
    ..Our data show that UK122 could potentially be developed as a new anticancer agent that prevents the invasion and metastasis of pancreatic cancer...
  23. doi request reprint Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells
    Bret Stephens
    Department of Molecular and Cellular Biology, University of Arizona, Tucson, USA
    Mol Cancer Ther 7:202-10. 2008
    ..These data support the hypothesis that PRL phosphatases regulate key pathways involved in tumorigenesis and metastasis and that knockdown of both PRL-1 and PRL-2 is required to disrupt PRL phosphatase function in pancreatic cancer cells...
  24. doi request reprint Adrenocortical carcinoma survival rates correlated to genomic copy number variants
    Elizabeth A Stephan
    Genetic Basis of Human Disease Division, Translational Genomics Research Institute, 445 North 5th Street, Phoenix, AZ 85004, USA
    Mol Cancer Ther 7:425-31. 2008
    ..These regions may hold prognostic indicators and offer therapeutic targets that can be used to develop novel treatments for aggressive tumors...
  25. ncbi request reprint Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer
    Steven L Warner
    Translational Research Division, Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004, USA
    Curr Oncol Rep 10:122-9. 2008
    ....
  26. doi request reprint Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial
    Tomislav Dragovich
    University of Arizona Health Sciences Center and Arizona Cancer Center, Tucson, AZ 85724, USA
    Am J Clin Oncol 31:157-62. 2008
    ..In addition, limited pharmacokinetic and pharmacodynamic analyses were preformed...
  27. pmc Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer
    Yoganand Balagurunathan
    Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004, USA
    Mol Cancer Ther 7:3071-80. 2008
    ..These validated gene combinations thus encompass a list of cell-surface targets that can be used to develop multimeric ligands for the imaging and treatment of pancreatic cancer...
  28. ncbi request reprint The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer
    Sangeeta Rojanala
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Mol Cancer Ther 3:451-7. 2004
    ..Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer...
  29. ncbi request reprint Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach
    Steven L Warner
    College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    Mol Cancer Ther 5:1764-73. 2006
    ..Although biological effects were observed only at relatively high concentrations, this chemical series provides an excellent starting point for drug optimization and further development...
  30. ncbi request reprint Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents
    Hong Wang
    The Translational Genomics Research Institute, Translational Drug Development Division, Phoenix, AZ 85004, USA
    Semin Oncol 33:513-20. 2006
    ..In this review, we discuss the feasibility of targeting loss-of-function mutations in tumor-suppressor genes for the identification of cancer-specific therapeutic agents...
  31. ncbi request reprint Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray
    Haiyong Han
    Department of Pathology, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Cancer Res 62:2890-6. 2002
    ..Potential up-regulated targets of note from this study include urokinase-type plasminogen activator receptor, serine/threonine kinase 15, thioredoxin reductase, and CDC28 protein kinase 2, as well as several others...
  32. ncbi request reprint A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies
    Lillian L Siu
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2157-66. 2002
    ..v. infusion daily for 5 days every 3 weeks in patients with advanced cancer...
  33. ncbi request reprint New drugs for patients with pancreatic cancer
    Daniel D Von Hoff
    Arizona Cancer Center, Tucson, Arizona 85724 5024, USA
    Curr Opin Oncol 14:621-7. 2002
    ....
  34. ncbi request reprint Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design
    Hariprasad Vankayalapati
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Mol Cancer Ther 2:283-94. 2003
    ....
  35. ncbi request reprint Targeting Aurora-2 kinase in cancer
    Steven L Warner
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Mol Cancer Ther 2:589-95. 2003
    ..These recent findings implicate aurora-2 as an important regulator of both genomic integrity and cell cycle progression in cancer cells and suggest that aurora-2 is an attractive target for anticancer drug development...
  36. ncbi request reprint A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
    Bahram Forouzesh
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:5540-9. 2003
    ..The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  37. ncbi request reprint A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies
    Miguel A Villalona-Calero
    Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 78229, USA
    Clin Cancer Res 8:75-85. 2002
    ..v. infusion for 5 days every 3 weeks; (b) recommend a dose for Phase II studies; (c) characterize its pharmacokinetic behavior; and (d) seek preliminary evidence of anticancer activity...
  38. ncbi request reprint Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer
    Phillip J Gray
    Arizona Cancer Center, Tucson 85724, USA
    Mol Cancer Ther 3:641-6. 2004
    ..These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer...
  39. ncbi request reprint PRL phosphatases as potential molecular targets in cancer
    Bret J Stephens
    Department of Molecular and Cellular Biology, University of Arizona, Tucson, USA
    Mol Cancer Ther 4:1653-61. 2005
    ..This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification...
  40. ncbi request reprint Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction
    Govindarajan Manikumar
    Research Triangle Institute, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Bioorg Med Chem Lett 14:5377-81. 2004
    ..We report the activity of these compounds as topoisomerase I poisons and their ability to inhibit growth of selected tumor cell lines...
  41. ncbi request reprint Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others
    Steven L Warner
    Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Semin Oncol 33:436-48. 2006
    ..Continued investigation of mechanisms regulating mitotic events will likely reveal additional proteins and pathways that could be potentially targeted and thereby provide more effective therapeutic options for cancer patients...
  42. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  43. ncbi request reprint Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases
    Weixin Wang
    Department of Surgery, University of Texas Health Science Center at San Antonio, 78229, USA
    Anticancer Res 22:559-64. 2002
    ..Pancreatic carcinoma resists chemotherapeutic mediation of apoptosis. Irofulven (MGI 114, 6-hydroxymethylacylfulvene) is a novel illudin S analogue that we have shown to induce caspase-mediated apoptosis in pancreatic carcinoma cell lines...
  44. ncbi request reprint Aurora sheds light on head and neck squamous cell carcinoma
    Haiyong Han
    Clin Cancer Res 12:5003-4. 2006
  45. ncbi request reprint Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element
    Laurence H Hurley
    University of Arizona, College of Pharmacy, Tucson, AZ, USA
    Semin Oncol 33:498-512. 2006
    ..Furthermore, TMPyP4 has been shown to repress c-MYC expression, and this effect is mediated through the silencer element. Last, the in vivo activity of TMPyP4 in xenograph models is presented...
  46. ncbi request reprint Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642)
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio 78245 3217, USA
    Invest New Drugs 20:261-70. 2002
    ..Lower doses in the range of 2,000-3,000 mg/kg were better tolerated, while still preserving antitumor activity. Evaluation of FB642 in phase I clinical trials of adult patients with advanced malignancies is currently ongoing...
  47. ncbi request reprint Translational research: stop, look, listen--if you expect to grow up tall
    Daniel D Von Hoff
    Arizona Cancer Center, University of Arizona, 1515 N Campbell Avenue P O Box 245024, Tucson 85724, Arizona, USA
    Cancer Biol Ther 1:718-20. 2002
  48. ncbi request reprint Does intraosseous equal intravenous? A pharmacokinetic study
    Daniel D Von Hoff
    Translational Genomics Research Institute and Arizona Cancer Center, University of Arizona, Phoenix, AZ 85721, USA
    Am J Emerg Med 26:31-8. 2008
    ..The objective of the study was to compare the pharmacokinetics of intraosseous vs intravenous administration of morphine sulfate in adults...
  49. ncbi request reprint The use of early sea urchin embryos in anticancer drug testing
    David Nishioka
    Department of Biology, Georgetown University, Washington, DC, USA
    Methods Mol Med 85:265-76. 2003
  50. ncbi request reprint Complex and simple
    Ephraim Philip Lansky
    Leuk Res 29:601-2. 2005
  51. ncbi request reprint A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms
    Lisa A Hammond
    Cancer Therapy and Research Center, University of San Antonio Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:1645-56. 2004
    ....
  52. ncbi request reprint Tumor-stroma interactions in pancreatic ductal adenocarcinoma
    Daruka Mahadevan
    Hematology Oncology, The University of Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 58724, USA
    Mol Cancer Ther 6:1186-97. 2007
    ..This review summarizes our current understanding of the mechanisms that potentially drive the DR in PDA and future possibilities for therapeutic targeting of this critical process...
  53. ncbi request reprint Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I
    Randy M Wadkins
    Department of Chemistry and Biochemistry, University of Mississippi, University, Mississippi 38677, USA
    Cancer Res 64:6679-83. 2004
    ..Taken together, our results suggest that CPTs with hydrophilic, hydrogen-bonding groups at the 7-position hold the promise of excellent clinical activity...
  54. ncbi request reprint Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity
    Randy M Wadkins
    University of Mississippi, Dept of Chemistry and Biochemistry, Coulter Hall, Room 409, University, MS 38677, USA
    Curr Med Chem Anticancer Agents 4:327-34. 2004
    ..We demonstrate that the cleavable complex stability conferred by each camptothecin analog is directly correlated with the induction of apoptosis and cytotoxicity to tumor cells...
  55. ncbi request reprint American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays
    Deborah Schrag
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
    J Clin Oncol 22:3631-8. 2004
    ..To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice...
  56. ncbi request reprint The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo
    Cory L Grand
    Arizona Cancer Center, Tucson, Arizona 85724, USA
    Mol Cancer Ther 1:565-73. 2002
    ..We believe that, because of the actions of TMPyP4 in decreasing both c-MYC protein levels and telomerase activity, as well as its anticancer effects in vivo, it is a worthwhile agent to pursue and develop further...

Research Grants18

  1. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2009
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  2. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  3. Targets to Therapeutics in Pancreatic Cancer
    Daniel Von Hoff; Fiscal Year: 2007
    ..We feel this effort, with new approaches to pancreatic cancer, concentrated in a P01, has a chance to make an impact on the disease. ..
  4. Workshop on Methods in Clinical Cancer Research
    Daniel Von Hoff; Fiscal Year: 2007
    ..Finally, a proven evaluation system is in place to make sure that the Workshop will meet its objectives. ..
  5. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2007
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  6. Aurora Kinase as a Therapeutic Target in Cancer
    Daniel Von Hoff; Fiscal Year: 2006
    ..Aurora kinase has considerable potential to be a very important target in patients' pancreatic cancers, against which new therapeutics can be designed and developed. ..
  7. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
    ..abstract_text> ..
  8. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel D Von Hoff; Fiscal Year: 2010
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..